Copertina

Review Article: Targeting Peroxisome Proliferator‐Activated Receptors in Primary Biliary Cholangitis

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Jörn M. Schattenberg, Jesus M. Banales, Gideon Hirschfield, Palak Trivedi, Edward E. Cable, Charles A. McWherter, Andrew N. Billin, Daria B. Crittenden, Grant Budas
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2026
Soggetti:	Alimentary Pharmacology & Therapeutics
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Letter: Therapeutic Targeting of PPARs in PBC —Additional Considerations. Authors' Reply
di: J. M. Schattenberg, et al.
Pubblicazione: (2026)

Editorial: Patient Reported Outcomes Provide Insight Into Disease Severity for People Living With Primary Sclerosing Cholangitis
di: Aisha Alawi, et al.
Pubblicazione: (2025)

Seladelpar Improved Itch, Itch‐Related Sleep Disturbance and Measures of Fatigue in Patients With Primary Biliary Cholangitis and Pruritus in the Phase 3 RESPONSE Trial
di: Cynthia Levy, et al.
Pubblicazione: (2026)

Longitudinal Relationship Between Elevated Liver Biochemical Tests and Negative Clinical Outcomes in Primary Biliary Cholangitis: A Population‐Based Study
di: Kris V. Kowdley, et al.
Pubblicazione: (2025)

Editorial: Peroxisome Proliferator‐Activated Receptor Agonists—Shifting the Goalpost From Biochemical Response to Symptom Directed Therapy in PBC
di: Henry H. Nguyen, et al.
Pubblicazione: (2026)

Quantitative MRCP and metrics of bile duct disease over time in patients with primary sclerosing cholangitis: A prospective study
di: Palak J. Trivedi, et al.
Pubblicazione: (2024)

Non‐Response to Obeticholic Acid Is Associated With Heightened Risks of Developing Clinical Events in Primary Biliary Cholangitis
di: Nadir Abbas, et al.
Pubblicazione: (2025)

Letter: Myokines Are Also Associated With Disease Course in Primary Biliary Cholangitis
di: Leyu Zhou, et al.
Pubblicazione: (2024)

Research Communication: Real‐World Clinical Experience With Seladelpar in Primary Biliary Cholangitis
di: Selena Z. Kuo, et al.
Pubblicazione: (2025)

Letter: Incremental Value and Stratified Interpretation of Dual Autoantibody Positivity in Primary Biliary Cholangitis
di: Ao Gao, et al.
Pubblicazione: (2026)

Lymphocyte‐to‐Monocyte Ratio as a Predictor of Recompensation in Patients With Decompensated Primary Biliary Cholangitis
di: Huiying Lin, et al.
Pubblicazione: (2025)

A Nationwide Assessment of Anticholestatic Therapy Uptake in Patients With Primary Biliary Cholangitis: Opportunities for Optimisation
di: Ellen Werner, et al.
Pubblicazione: (2026)

Long‐Term Use of Fenofibrate as Second‐Line Therapy in Primary Biliary Cholangitis: A Retrospective Study
di: Mariko Maxwell, et al.
Pubblicazione: (2026)

Letter: Incremental Value and Stratified Interpretation of Dual Autoantibody Positivity in Primary Biliary Cholangitis. Authors' Reply
di: Hong‐Li Liu, et al.
Pubblicazione: (2026)

Letter: Increased Prevalence of Visceral Obesity in Nonresponder Patients With Primary Biliary Cholangitis Based on Computed Tomography
di: Bo Li, et al.
Pubblicazione: (2024)

Letter on ‘Non‐Response to Obeticholic Acid Is Associated With Heightened Risks of Developing Clinical Events in Primary Biliary Cholangitis’
di: Yi Pei, et al.
Pubblicazione: (2025)

Letter: Increased Prevalence of Visceral Obesity in Nonresponder Patients With Primary Biliary Cholangitis Based on Computed Tomography—Authors' Reply
di: Conrado Fernandez‐Rodriguez, et al.
Pubblicazione: (2024)

Dual Positivity for AMA / AMA ‐ M2 and Anti‐gp210/sp100 Shows Highest Diagnostic Value for Primary Biliary Cholangitis
di: Hong‐Li Liu, et al.
Pubblicazione: (2026)

Review Article: The Evolving Role of GLP ‐1 Receptor Agonists in Gastroenterology Practice
di: Sydney Pomenti, et al.
Pubblicazione: (2025)

Review Article: GLP‐1 Receptor Agonists and Glucagon/GIP/GLP‐1 Receptor Dual or Triple Agonists—Mechanism of Action and Emerging Therapeutic Landscape in MASLD
di: Maryam Zafer, et al.
Pubblicazione: (2025)

Short‐term reduction of dietary gluten improves metabolic‐dysfunction associated steatotic liver disease: A randomised, controlled proof‐of‐concept study
di: Angelo Armandi, et al.
Pubblicazione: (2024)

Primary Sclerosing Cholangitis in the Absence of Inflammatory Bowel Disease Increases the Risk of Colorectal Cancer: A Multi‐Centre Propensity Score Matched Analysis
di: Saqr Alsakarneh, et al.
Pubblicazione: (2025)

Review Article: Individualised Management of Reflux‐Like Symptoms—Strategies Beyond Acid Suppression
di: Peter J. Kahrilas, et al.
Pubblicazione: (2025)

Review Article: Extending the Frontiers of Intestinal Ultrasound Knowledge, Performance and Expansion
di: Cathy Lu, et al.
Pubblicazione: (2025)

Review Article: Drug Approval for Gastroparesis—Suggestions for Improving the Process for Positive Results
di: Michael Camilleri, et al.
Pubblicazione: (2026)

Editorial for ‘Review Article: Extending the Frontiers of Intestinal Ultrasound Knowledge, Performance, and Expansion’
di: Cameron Kendall, et al.
Pubblicazione: (2025)

Review Article: Green Management of IBD—New Paradigms for an Eco‐Friendly Approach
di: Giovanni Cammarota, et al.
Pubblicazione: (2024)

Review Article: TL1A Inhibitors in IBD ‐ Mechanistic Rationale and Clinical Evidence
di: Manjeet Kumar Goyal, et al.
Pubblicazione: (2026)

Review Article: Novel Enzyme Therapy Design for Gluten Peptide Digestion Through Exopeptidase Supplementation
di: Erin R. Bonner, et al.
Pubblicazione: (2025)

Review Article: Drug‐Induced Liver Injury Associated With Antibody‐Based Therapies in Haematologic Malignancies
di: Mengmeng Lin, et al.
Pubblicazione: (2025)

Review Article: Classic Bismuth Quadruple Therapy for Helicobacter pylori Infection—Questions Focused on Clinical Practice
di: Javier P. Gisbert, et al.
Pubblicazione: (2026)

Review Article: Surrogate Endpoints to Assess Treatment Efficacy in Disorders of Gut–Brain Interaction of Lower Gastrointestinal Tract
di: Michael Camilleri, et al.
Pubblicazione: (2025)

Letter: From Safety to Precision—Optimising the Use of GLP‐1 Receptor Agonists in Gastroenterology
di: Joëlle St‐Pierre, et al.
Pubblicazione: (2026)

Impact of GLP‐1 Receptor Agonists on Alcohol‐Related Liver Disease Development and Progression in Alcohol Use Disorder
di: Chia‐Chih Kuo, et al.
Pubblicazione: (2025)

Some Risks of Gastrointestinal Adverse Events Associated With Glucagon‐Like PEPTIDE‐1 Receptor Agonists Are Likely Explained by BMI
di: Benjamin Douglas Liu, et al.
Pubblicazione: (2025)

Letter: Methodological Considerations in Comparing Liver Outcomes of Glucagon‐Like Peptide‐1 Receptor and Sodium Glucose Cotransporter‐2 Inhibitors
di: Cheng‐Hsien Hung, et al.
Pubblicazione: (2025)

IL23 Receptor Polymorphism Is a Predictor of Anti‐Tumour Necrosis Factor‐α‐Induced Paradoxical Psoriasis in Inflammatory Bowel Disease
di: Navneet Natt, et al.
Pubblicazione: (2025)

Letter: Selective FGFR1c/KLB Activation in MASH—A Mechanistic Dilemma?
di: Cuiyun Tao, et al.
Pubblicazione: (2025)

Effects of Resmetirom on Metabolic‐Dysfunction Associated Steatohepatitis in Patients With Weight Loss and/or Diabetes Taking Glucagon‐Like Peptide‐1 Receptor Agonists and Other Diabetes Therapies: A Secondary Analysis of the MAESTRO ‐ NASH Trial
di: Mazen Noureddin, et al.
Pubblicazione: (2025)

Assessing Major Adverse Liver Outcomes With Baclofen Compared to Acamprosate in Compensated Alcohol‐Associated Cirrhosis
di: Yee Hui Yeo, et al.
Pubblicazione: (2026)